GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Market Cap

Incyte (LTS:0J9P) Market Cap : $13,206 Mil (As of Dec. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Incyte Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Incyte's share price for the quarter that ended in Sep. 2024 was $66.28. Incyte's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 193 Mil. Therefore, Incyte's market cap for the quarter that ended in Sep. 2024 was $12,779 Mil.

Incyte's quarterly market cap declined from Mar. 2024 ($12,771 Mil) to Jun. 2024 ($11,579 Mil) but then increased from Jun. 2024 ($11,579 Mil) to Sep. 2024 ($12,779 Mil).

Incyte's annual market cap increased from Dec. 2021 ($16,528 Mil) to Dec. 2022 ($17,725 Mil) but then declined from Dec. 2022 ($17,725 Mil) to Dec. 2023 ($14,020 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Incyte's Enterprise Value for Today is $11,468 Mil.


Incyte Market Cap Historical Data

The historical data trend for Incyte's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Market Cap Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19,444.04 19,382.55 16,528.24 17,724.51 14,020.18

Incyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,973.71 14,020.18 12,771.30 11,578.61 12,778.65

Competitive Comparison of Incyte's Market Cap

For the Biotechnology subindustry, Incyte's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Market Cap distribution charts can be found below:

* The bar in red indicates where Incyte's Market Cap falls into.



Incyte Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Incyte's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$62.51*224.287
=$14,020

Incyte's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$66.28*192.798
=$12,779

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte  (LTS:0J9P) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Incyte Market Cap Related Terms

Thank you for viewing the detailed overview of Incyte's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines